Prelude Therapeutics Profit Margin

Prelude Therapeutics (PRLD) currently reports a profit margin of -4.65% as of March 2026. That compares with -31.96% in the prior-year period — up 85.4% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Prelude Therapeutics's profit margin history and peer comparisons.

Prelude Therapeutics's profit margin increased from -31.96% to -4.65% — a 85.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Prelude Therapeutics's profit margin of -4.65% is lower than the Healthcare sector average of 15.58%. That is roughly 3085.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Prelude Therapeutics's current -4.65% should be judged against Healthcare norms (sector average: 15.58%) and against PRLD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4.65%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Prelude Therapeutics, and consider following PRLD for alerts when major investors trade the stock.